BostonGene Announces Partnership with National Institutes of Health

Precision Medicine Studies Underway to Enable Dynamic Monitoring of Disease Progression and Response to Treatment

WALTHAM, Mass.--()--BostonGene Corporation (BostonGene), a biomedical software company, today announced its partnership with the National Institutes of Health (NIH) including the National Cancer Institute (NCI) and the National Institute of Allergy and Infectious Diseases (NIAID).

BostonGene’s solution will provide NCI and NIAID with an interpretation and visualization of a patient's next-generation sequencing (NGS) information within the landscape of a patient’s genetic and genomic data at a desired level of complexity. The solution will identify all significant somatic alterations, evaluation of protein expression, estimation of tumor heterogeneity, prediction of neoantigens, tumor clonality, hereditary predisposition, viral infestation and pharmacogenomics among other molecular features. BostonGene generates a visually-appealing and self-explanatory tumor schematics, called MF Portrait™, depicting tumor activity, tumor cellular composition, activity of immune-microenvironment and other tumor-associated processes.

“Immuno- and targeted therapies are the most promising and rapidly developing treatments for cancer. BostonGene is thrilled to be partnering with NIH to provide sophisticated data analytics to produce viable treatment options personalized for each patient. Our mission is to treat the patient, not treat the diagnosis,” said Andrew Feinberg, President and CEO of BostonGene.

About BostonGene Corporation

BostonGene Corporation is pioneering the use of biomedical software for advanced patient analysis and personalized therapy decision making in the fight against cancer. BostonGene’s unique solution performs sophisticated analytics to aid clinicians in their evaluation of viable treatment options for each patient's individual genetics, tumor and tumor microenvironment, clinical characteristics and disease profile. BostonGene’s mission is to enable physicians to provide every patient with the highest probability of survival through optimal cancer treatments using advanced, personalized therapies. For more information, visit BostonGene at http://www.BostonGene.com.

Contacts

BostonGene
Erin O’Reilly
+1-781-366-7049
Erin.Oreilly@BostonGene.com

Release Summary

BostonGene Announces Partnership with National Institutes of Health

Contacts

BostonGene
Erin O’Reilly
+1-781-366-7049
Erin.Oreilly@BostonGene.com